This review highlights significant sex differences in the epidemiology, presentation, and treatment response of cardiac arrhythmias, emphasizing the need for better utilization of therapies like ICD and CRT in women.
Answers are grounded in this paper and cite their sources.
Sex differences may inform arrhythmia risk assessment; leaves open prospective trials to address device underutilization in women.
There are important gender differences in cardiac electrophysiology that affect the epidemiology, presentation, and prognosis of various arrhythmias. Women have been noted to have higher resting heart rates compared to men. They also have a longer QT interval, which puts them at an increased risk for drug-induced torsades de pointes. Women with atrial fibrillation are at a higher risk of stroke, and they are less likely to receive anticoagulation and ablation procedures compared to men. Women have a lower risk of sudden cardiac death and are less likely to have known coronary artery disease at the time of an event compared to men. Both men and women have been shown to derive an equal survival benefit from implantable cardioverter defibrillators and cardiac resynchronization therapy, although these devices are significantly underutilized in women. Women also appear to have a better response to cardiac resynchronization therapy in terms of reduced numbers of hospitalizations and more robust reverse ventricular remodeling. Further studies are required to elucidate the underlying pathophysiology of these sex differences in cardiac arrhythmias.
No takes yet. Share an insight, caveat, or question.
Curtis et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: